- Home
- PXLW vs CUE Comparison
PXLW vs CUE Comparison
Compare PXLW & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PXLW
- CUE
- Stock Information
- Founded
- PXLW 1997
- CUE 2014
- Country
- PXLW United States
- CUE United States
- Employees
- PXLW N/A
- CUE N/A
- Industry
- PXLW Semiconductors
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- PXLW Technology
- CUE Health Care
- Exchange
- PXLW Nasdaq
- CUE Nasdaq
- Market Cap
- PXLW 50.2M
- CUE 56.1M
- IPO Year
- PXLW 2000
- CUE 2018
- Fundamental
- Price
- PXLW $11.52
- CUE $0.75
- Analyst Decision
- PXLW Strong Buy
- CUE Strong Buy
- Analyst Count
- PXLW 3
- CUE 2
- Target Price
- PXLW $13.67
- CUE $3.00
- AVG Volume (30 Days)
- PXLW 198.7K
- CUE 187.3K
- Earning Date
- PXLW 11-11-2025
- CUE 11-13-2025
- Dividend Yield
- PXLW N/A
- CUE N/A
- EPS Growth
- PXLW N/A
- CUE N/A
- EPS
- PXLW N/A
- CUE N/A
- Revenue
- PXLW $33,961,000.00
- CUE $8,286,000.00
- Revenue This Year
- PXLW N/A
- CUE N/A
- Revenue Next Year
- PXLW $25.33
- CUE $13.27
- P/E Ratio
- PXLW N/A
- CUE N/A
- Revenue Growth
- PXLW N/A
- CUE N/A
- 52 Week Low
- PXLW $4.67
- CUE $0.54
- 52 Week High
- PXLW $15.03
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- PXLW 53.40
- CUE 54.66
- Support Level
- PXLW $9.80
- CUE $0.69
- Resistance Level
- PXLW $15.00
- CUE $0.73
- Average True Range (ATR)
- PXLW 1.38
- CUE 0.04
- MACD
- PXLW 0.14
- CUE 0.01
- Stochastic Oscillator
- PXLW 40.13
- CUE 85.70
About PXLW Pixelworks Inc.
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.